doi: 10.1007/978-1-4684-8914-9_30.
Mitigation of experimental allergic encephalomyelitis by cathepsin D inhibition
- PMID: 317560
- DOI: 10.1007/978-1-4684-8914-9_30
Item in Clipboard
Mitigation of experimental allergic encephalomyelitis by cathepsin D inhibition
Adv Exp Med Biol.
1979.
Abstract
Intraperitoneal treatment with the enzyme inhibitor, pepstatin, of BSVS mice, guinea pigs and Lewis rats which were sensitized with guinea pig spinal cord and pertussis vaccine resulted in complete or partial suppression of paralysis dependent on the species studied and alterations of histological signs of experimental allergic encephalomyelitis (EAE). The effect was dose-dependent but had no relationship to the age of the experimental animal at the time of the experiment.
Similar articles
-
Treatment of experimental allergic encephalomyelitis with an inhibitor of cathepsin D (pepstatin).Neurochem Res. 1978 Apr;3(2):185-94. doi: 10.1007/BF00964059. Neurochem Res. 1978. PMID: 307703
-
Niridazole suppression of experimental allergic encephalomyelitis in Lewis rats.J Immunol. 1977 Jun;118(6):2151-4. J Immunol. 1977. PMID: 301156
-
Suppression of experimental allergic encephalomyelitis by alpha 2-macroglobulin.Immunology. 1991 May;73(1):58-63. Immunology. 1991. PMID: 1710603 Free PMC article.
-
Proteolytic enzymes in ordinary, hyperacute, monocytic and passive transfer forms of experimental allergic encephalomyelitis.Brain Res. 1977 Mar 4;123(1):147-57. doi: 10.1016/0006-8993(77)90649-7. Brain Res. 1977. PMID: 843913
-
Pepstatins: aspartic proteinase inhibitors having potential therapeutic applications.Med Res Rev. 1993 Mar;13(2):199-208. doi: 10.1002/med.2610130206. Med Res Rev. 1993. PMID: 8445958 Review. No abstract available.
Cited by
-
The multiple sclerosis degradome: enzymatic cascades in development and progression of central nervous system inflammatory disease.Curr Top Microbiol Immunol. 2008;318:133-75. doi: 10.1007/978-3-540-73677-6_6. Curr Top Microbiol Immunol. 2008. PMID: 18219817 Free PMC article. Review.